CA2602291C - Treatments for preventing or reducing adverse effects in a patient having decreased left ventricular function - Google Patents

Treatments for preventing or reducing adverse effects in a patient having decreased left ventricular function Download PDF

Info

Publication number
CA2602291C
CA2602291C CA2602291A CA2602291A CA2602291C CA 2602291 C CA2602291 C CA 2602291C CA 2602291 A CA2602291 A CA 2602291A CA 2602291 A CA2602291 A CA 2602291A CA 2602291 C CA2602291 C CA 2602291C
Authority
CA
Canada
Prior art keywords
surgery
aica riboside
adenosine
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2602291A
Other languages
English (en)
French (fr)
Other versions
CA2602291A1 (en
Inventor
Dennis T. Mangano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PERICOR THERAPEUTICS Inc
Original Assignee
PERICOR THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PERICOR THERAPEUTICS Inc filed Critical PERICOR THERAPEUTICS Inc
Publication of CA2602291A1 publication Critical patent/CA2602291A1/en
Application granted granted Critical
Publication of CA2602291C publication Critical patent/CA2602291C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2602291A 2005-03-28 2006-03-28 Treatments for preventing or reducing adverse effects in a patient having decreased left ventricular function Expired - Lifetime CA2602291C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66607105P 2005-03-28 2005-03-28
US60/666,071 2005-03-28
PCT/US2006/011422 WO2006105167A2 (en) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient

Publications (2)

Publication Number Publication Date
CA2602291A1 CA2602291A1 (en) 2006-10-05
CA2602291C true CA2602291C (en) 2015-08-11

Family

ID=37054068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2602291A Expired - Lifetime CA2602291C (en) 2005-03-28 2006-03-28 Treatments for preventing or reducing adverse effects in a patient having decreased left ventricular function

Country Status (14)

Country Link
US (3) US8993527B2 (enExample)
EP (3) EP2594273A1 (enExample)
JP (9) JP2008534601A (enExample)
KR (1) KR20070121026A (enExample)
CN (1) CN101184495B (enExample)
AU (1) AU2006230242B2 (enExample)
BR (1) BRPI0608654C1 (enExample)
CA (1) CA2602291C (enExample)
MX (1) MX2007012045A (enExample)
NO (1) NO342207B1 (enExample)
NZ (1) NZ561649A (enExample)
SG (3) SG194352A1 (enExample)
WO (1) WO2006105167A2 (enExample)
ZA (1) ZA200708277B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006230242B2 (en) 2005-03-28 2013-05-30 Pericor Therapeutics, Inc. Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
DE102008007216A1 (de) 2007-05-29 2008-12-11 Samsung Electro - Mechanics Co., Ltd., Suwon Gedruckte Leiterplatte und Herstellungsverfahren derselben
EP2349284B1 (en) * 2008-10-03 2016-11-23 Pericor Therapeutics, Inc. Treatment of acute decompensated heart failure
EP2512489A4 (en) * 2009-12-15 2014-04-02 Merck Sharp & Dohme FORMULATIONS FROM ACADESIN
US8489182B2 (en) 2011-10-18 2013-07-16 General Electric Company System and method of quality analysis in acquisition of ambulatory electrocardiography device data
US11160879B2 (en) 2014-01-15 2021-11-02 Masamichi Yamamoto Transgenic animal for visualization of ATP and use thereof
EP3107548B8 (en) 2014-02-20 2022-07-20 Otitopic Inc. Dry powder formulations for inhalation
CN104140438B (zh) * 2014-06-11 2017-01-18 苏州景泓生物技术有限公司 5‑氨基‑4‑氨甲酰咪唑核苷碳环类似物的合成方法
CA2991760C (en) 2014-07-31 2025-05-06 Aspeya US Inc. DRY INHALATION POWDER FORMULATIONS
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
WO2018092911A1 (ja) * 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤
JP6937134B2 (ja) 2016-11-21 2021-09-22 株式会社スタージェン 細胞内ａｔｐ増強剤
WO2019039438A1 (ja) * 2017-08-21 2019-02-28 国立大学法人三重大学 非ヒト哺乳類の脳梗塞モデルによる観察方法及び非ヒト哺乳類の脳梗塞モデルによる観察装置
AU2018336787B2 (en) 2017-09-19 2024-05-30 Corflow Therapeutics Ag Intracoronary characterization of microvascular obstruction (MVO) and myocardial infarction
EP4040991A4 (en) * 2019-10-09 2024-01-24 Mayo Foundation for Medical Education and Research TREATMENT OF GASTROINTESTINAL DISORDERS
EP3866176A1 (en) * 2020-02-17 2021-08-18 Siemens Healthcare GmbH Machine-based risk prediction for peri-procedural myocardial infarction or complication from medical data
EP4792852A2 (en) 2020-05-22 2026-08-19 CorFlow Therapeutics AG Controlled flow infusion microvascular dysfunction diagnostic and therapy
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
US20260102457A1 (en) * 2022-09-26 2026-04-16 The Penn State Research Foundation Anticoagulant-peptide nanogranules for thrombosis-actuated anticoagulation
KR20250161553A (ko) * 2023-03-13 2025-11-17 울트라사운드 에이아이, 인코포레이티드 의료 이미징을 통한 포괄적인 의료 진단, 예후, 및 치료 최적화를 위한 인공 지능 시스템

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1645976A1 (de) 1966-06-18 1971-01-21 Ajinomoto Kk Verfahren zur Herstellung von Adenosin und 2',3'-O-Isopropylidenadenosin
JPS4944349B1 (enExample) * 1967-06-16 1974-11-27
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AT350735B (de) 1976-08-06 1979-06-11 Hoffmann La Roche Verfahren zur herstellung von neuen ribo- furanosyl-imidazolderivaten
AU529815B2 (en) * 1981-05-15 1983-06-23 Fisons Plc Optically active imidazole derivatives
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US4912092A (en) 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5118601A (en) * 1986-03-27 1992-06-02 The Regents Of The University Of California Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
US5008251A (en) * 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
FI875245A0 (fi) 1986-03-27 1987-11-27 Harry Edward Gruber Foerfarande foer oekande av utsoendringen av adenosin.
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5200525A (en) * 1989-01-24 1993-04-06 Gensia Pharmaceuticals Anti-seizure compounds
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
FI921092A7 (fi) * 1989-09-15 1992-03-13 Gensia Pharma Menetelmä neurodegeneratiivisten tilojen hoitamiseksi
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
IL99125A0 (en) * 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL99124A (en) * 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
JPH08504765A (ja) * 1992-12-16 1996-05-21 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖性の置換５−チアピリミジノンおよび５−セレノピリミジノン化合物
IL108524A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5366960A (en) * 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5629298A (en) * 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
US5645128A (en) * 1995-06-05 1997-07-08 Schwall; Charles F. Fire safety grease seal
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
WO2003037371A2 (en) 2001-10-31 2003-05-08 Universite Libre De Bruxelles Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
ES2192495B1 (es) * 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
AU2006230242B2 (en) 2005-03-28 2013-05-30 Pericor Therapeutics, Inc. Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
US20070082859A1 (en) 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
EP2247183A4 (en) 2008-01-25 2011-06-22 John E Foker METHOD AND COMPOSITIONS FOR INHIBITING PROGRESS FOR CHRONIC HEART FAILURE

Also Published As

Publication number Publication date
WO2006105167A3 (en) 2007-05-10
EP2594273A1 (en) 2013-05-22
US9539274B2 (en) 2017-01-10
MX2007012045A (es) 2008-01-16
JP2020152737A (ja) 2020-09-24
NZ561649A (en) 2011-02-25
KR20070121026A (ko) 2007-12-26
JP2022093641A (ja) 2022-06-23
NO20075400L (no) 2007-12-19
BRPI0608654B8 (pt) 2020-10-27
JP2013010795A (ja) 2013-01-17
JP2019089853A (ja) 2019-06-13
BRPI0608654C1 (pt) 2021-05-25
JP2025084893A (ja) 2025-06-03
JP7093739B2 (ja) 2022-06-30
WO2006105167A2 (en) 2006-10-05
US20150272978A1 (en) 2015-10-01
ZA200708277B (en) 2011-03-30
SG194352A1 (en) 2013-11-29
NO342207B1 (no) 2018-04-16
SG160425A1 (en) 2010-04-29
CN101184495B (zh) 2011-09-14
AU2006230242A1 (en) 2006-10-05
BRPI0608654A2 (pt) 2010-01-19
JP2017057222A (ja) 2017-03-23
CN101184495A (zh) 2008-05-21
EP3132796A1 (en) 2017-02-22
JP2013010794A (ja) 2013-01-17
BRPI0608654B1 (pt) 2020-09-29
CA2602291A1 (en) 2006-10-05
JP2008534601A (ja) 2008-08-28
JP6122417B2 (ja) 2017-04-26
US20170216335A1 (en) 2017-08-03
US20060293273A1 (en) 2006-12-28
EP1863497A2 (en) 2007-12-12
SG10201704913RA (en) 2017-07-28
US8993527B2 (en) 2015-03-31
EP1863497A4 (en) 2009-08-12
AU2006230242B2 (en) 2013-05-30
JP2015057436A (ja) 2015-03-26

Similar Documents

Publication Publication Date Title
US9539274B2 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
US4912092A (en) Methods for increasing extracellular adenosine and for stabilizing mast cells
US5658889A (en) Method and compounds for aica riboside delivery and for lowering blood glucose
EP0427799B1 (en) Method and compounds for aica riboside delivery and for lowering blood glucose
US5030623A (en) Methods for increasing extracellular adenosine and for stabilizing mast cells
US5008251A (en) Method of treating autism
US5118601A (en) Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
EP0623348A1 (en) The use of AICA riboside and ribavirin for the preparation of a medicament for the treatment of allergies
US6103702A (en) Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
HK1234668A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
CA2089145A1 (en) Methods of preventing or decreasing tissue damage by novel antioxidants and free radical scavengers

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409